Reportedly, GRg3 enhances the cytotoxicity of chemotherapy in gastric (Wang G et al., 2022) and colon cancers (Hong et al., 2020) by modulating the PI3K/AKT pathway, promoting apoptosis, and enhancing the chemosensitivity of both cisplatin and 5-FU, and reversing the chemoresistance of sorafenib and 5-FU. Here, AKT1 is linked to malignant colon neoplasm.